T ype 2 diabetes is an emerging problem in the paediatric population. Paediatricians and paediatric endocrinologists are struggling with how to best assess, predict and treat cardiovascular risk factors in these patients. There is a notable lack of consensus in how to proceed, even among experts in the field. There are very limited data from quality trials in established paediatric type 2 diabetes. We address the available information regarding traditional and non-traditional indices of cardiovascular risk, including examination findings, biochemical markers and non-invasive imaging modalities. We discuss the utility and pitfalls of applying knowledge gained in adult medicine to the paediatric population. Potential treatment strategies are reviewed, including the currently available pharmaceutical options, with the acknowledgement that there are few drugs formally approved in the paediatric population.
Introduction
The incidence of type 2 diabetes (T2DM) in youth is rapidly increasing, in tandem with the child obesity epidemic. 1 The precursor condition, which involves insulin resistance and hyperinsulinaemia with normoglycaemia, is even more common. A recent study of children with marked obesity found that the majority displayed impaired glucose tolerance, whereas just a small percentage met the formal criteria for T2DM. 2 The National Health And Nutrition Examination Survey (NHANES) 1999-2002 database contains a large sample of adolescents with self-reported diabetes (n=4,370) as well as a subsample of adolescents without self-reported diabetes (n=1,496). Of those adolescents with self-reported diabetes, 71% were characterised as having type 1 diabetes (T1DM) and 29% were characterised as having T2DM. Of the subsample, approximately 11% of patients were diagnosed with impaired fasting glucose (IFG, glucose > 100 mg/dL, [5. 55 mmol/L]). When adjusting for population-based sample weights, these numbers were equivalent to 39,000 US youths with T2DM and 2.7 million US youths with IFG. 3 Obesity is the most common cause of insulin resistance in children. Insulin resistance, physical inactivity and obesity are considered to be the main progenitors of the various pathophysiologies found in the metabolic syndrome, including atherogenic dyslipidaemia, hypertension, hyperuricaemia, a pro-thrombotic state and a pro-inflammatory state. 4 The definition of metabolic syndrome in adults involves the clustering of certain cardiovascular disease (CVD) risk factors. A loose consensus of the definition of metabolic syndrome in children includes the presence of three or more CVD risk factors (central obesity, hypertension, low levels of high-density lipoprotein (HDL) cholesterol, elevated glucose and triglyceride levels). 5 In a multivariable logistic regression analysis, a family history of CVD, smoking and the metabolic syndrome were each independently associated with odds ratios of 3.1 (95% confidence interval [CI] 1.7-5.7; p<0.001), 4.5 (95% CI 2.3-8.7; p<0.001), and 2.0 (95% CI 1.1-3.6; p=0.02), respectively, for the future incidence of an acute coronary syndrome. When the three risk factors were combined, the odds ratio jumped to 7.1; (95% CI 2.4-21.0; p<0.001). 6 Although there are no formal guidelines in place for stepwise evaluation and intervention in adolescents with features of the metabolic syndrome, the presence of such features in this population warrants increased clinical support.
Recent studies show that the pathological processes that lead to atherosclerotic CVD can begin in childhood in patients with multiple risk factors. 7 The traditional adult risk factors for CVD that are thought to apply also to adolescents include high blood pressure, dyslipidaemia, glucose intolerance, smoking, age, male sex, obesity and family history. Furthermore, adolescents who are obese have a greater risk of morbidity and mortality due to coronary vascular disease and atherosclerosis in adulthood, regardless of their adult weight. 8 Because of the tremendous increase in childhood obesity and childhood insulin resistance and because CVD is the most common cause of death in Western populations, there is a significant need to identify, modify and eliminate pre-emptively the factors known to advance the atherosclerotic process. 9 
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Vascular disease in paediatric type 2 diabetes: the state of the art
The approach to a screening evaluation for CVD risk in children and adolescents can be divided into different components: the history, physical findings and biochemical assessments. In addition, early alterations of vascular biology suggestive of CVD in children can be demonstrated using various imaging modalities. A challenging component of CVD therapeutic risk assessment and modification in children and adolescents is determining whether and how risk factors for CVD and its pathophysiology in children differ from those in adults. These unknowns make the prediction of future CVD events difficult. The uncertain safety profiles of existing pharmacological therapies in the paediatric population and the challenges of cost-effectiveness considerations of lifelong preventive therapies further confound treatment recommendations for CVD risk modification in children, including (but not limited to) those with diabetes mellitus (DM).
Assessing CVD risk: history, physical examination and the laboratory History
The simplest method for assessment of CVD risk involves taking a thorough history. Family history plays a pivotal role in the assessment of CVD risk among children, especially those with obesity, metabolic syndrome and T2DM. Many studies show that a family history of premature coronary artery disease (CAD) is a significant risk factor for the same thing in first-degree relatives. 6, 7, 10 With a significant family history of CVD (defined as CAD, myocardial infarction or stroke), a child is more likely to be obese and to have higher levels of lipoprotein (a) [Lp(a)] and apolipoprotein B (Apo B). 11 There is also a strong association between the prevalence of risk factors in parents and children, including increased waist circumference, body mass index (BMI), blood pressure, triglycerides and total cholesterol. 12 Children who are obese and who have a family history of T2DM have the highest risk of impaired glucose tolerance. 13 Using multiple linear regression analysis, a family history of T2DM remained a significant determinant of haemoglobin A 1C (HbA 1C ), diastolic blood pressure and the HDL cholesterol to total cholesterol ratio even when subjects were controlled for the waist-to-hip ratio as a measure of adiposity. 14 In addition to the family history, each child's own medical history should be assessed for medical problems or therapies that may put the child at risk for metabolic derangement. Examples include the chronic use of steroids, organ transplantation or chemotherapy.
Anthropometric evaluation
The Framingham Heart Study established that there was a significant positive association between cardiovascular events and weight in both men and women. 15 Several studies have firmly established that increased central obesity and a higher BMI in childhood are associated with CVD. Intimamedia thickness (IMT), further discussed later, is greater in obese children. 16 Early evidence of vascular change is more prevalent in obese children. 17 These changes are related to the CVD risk factors of hypertension, chronic inflammation and altered glucose regulation. While the absolute degree of obesity is integral to increased CVD risk, the distribution of adipose tissue can also determine future morbidity and mortality. 18 A predominantly central fat mass distribution as measured by the waist-to-hip ratio (WHR) is associated with greater CVD risk than gluteal-femoral fat distribution. 19, 20 In a population sample of girls, waist circumference was significantly associated with a greater CVD risk, independent of overall degree of adiposity. 21 WHR is likely to be the best anthropometric measure of CVD risk in children, significantly associated with levels of Lp(a) in children with both type 1 and type 2 diabetes, and a better predictor of obesity-related co-morbidity than BMI. 22, 23 Truncal skin fold measurements can complement the WHR, reflecting the distribution of adiposity and dual energy X-ray absorptiometry (DEXA)determined total central fat mass levels; independent of other anthropometric measures, this measure is associated with total cholesterol to HDL ratio, the low-density lipoprotein cholesterol (LDL-C) level, triacylglycerol and Apo B levels. 24 
Hypertension
Hypertension is a well-known CVD risk factor. Development of metabolic dysfunction arising from hyperinsulinaemia, including fluid overload, increased sympathetic nervous system activity and sodium retention, promotes hypertension. 25 More than half of all adults who initially present with T2DM have hypertension, and it is common for an adolescent to have hypertension and renal dysfunction even when he or she is relatively newly diagnosed with DM. 26, 27 Studies show conflicting data on whether the interaction between hypertension and insulin resistance can be independent of obesity. 15, 28 In the Coronary Artery Risk Development In young Adults (CARDIA) study, the association between insulin levels and hypertension was evident independent of weight. 29 
Biochemical assessment
The types of biochemical assessment in adolescents at risk for CVD are essentially extrapolated from adult data in this area. Identifying risk factors for the development of CVD includes the evaluation of traditional biochemical parameters such as lipid profiles and glucose metabolism. 30 Multiple early studies, including the Bogalusa Heart Study and the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study, demonstrated that risk factors for CVD include elevated serum total cholesterol and hyperglycaemia. 7, 31 Elevated LDL-C levels in childhood can lead to adult dyslipidaemia and can be associated with obesity and hypertension. 32 Enhanced knowledge of the role of inflammation in cardiovascular disease has led to the investigation of potential serum markers of inflammation and endothelial activation. These markers include indices such as C-reactive protein (CRP), fibrinogen (FB), interleukin-6 (IL-6), intercellular cell adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1). CRP has been studied extensively in adults and is associated with peripheral arterial disease, myocardial infarctions and cerebrovascular accidents, yet it remains unclear whether CRP is a causative agent or a byproduct of active inflammation. [33] [34] [35] Children with REVIEW hypertension have significantly higher levels of several inflammatory markers and indices of endothelial activation compared with normotensive controls. 36 In particular, CRP was an independent determinant of both systolic and diastolic blood pressure. 36 Highlighting the contribution of genetics to CVD risk, offspring of parents with essential hypertension have higher levels of CRP than control subjects, even after adjustment for age, sex and BMI. 37 Beyond CRP, other circulating inflammatory markers may contribute to CVD risk assessment in children with DM. Based largely on data from adults, these may include fibrinogen, interleukin-6 (IL-6) and intracellular adhesion molecules (ICAMs). Fibrinogen is recognised as an independent risk factor for atherosclerosis in adults; in analysis of data from approximately 300 schoolchildren in Japan using a multiple linear regression analysis, it was independently associated with total cholesterol in boys, with BMI in girls and with serum CRP and HbA 1C in both sexes. 38 IL-6 is another inflammatory biomarker of interest, especially in the setting of perturbed glucose metabolism, as it is associated with insulin resistance and obesity in adults. 39 IL-6 regulates CRP production and lipid metabolism, and inhibits insulinmediated glucose transport. Few data exist on the prospective role of IL-6 in determining CVD risk in adolescents. In adults, ICAMs are reliable markers of endothelial activation and inflammation, 40 and are elevated in obese prepubertal children compared with non-obese children. 41 ICAMs are independently associated with total cholesterol, BMI and measures of insulin resistance. Additional studies are needed to determine the utility of measuring cell adhesion molecules in adolescents when determining future CVD risk.
Measurement and quantification of CVD: vascular biology
The methods discussed above clearly suggest correlative relationships to CVD but do not allow for objective measurement and quantification of CVD within the vasculature. For this reason, and due to the fact that clinical evidence of atherosclerotic CVD is rarely apparent upon examination of the paediatric patient, there is strong interest in imaging and other modalities that will provide early, objective measurements of vascular pathology. Methods such as these are critical for research into specific interventions. In general, these modalities assess abnormalities of three vascular parameters: vascular physiology, mechanics and anatomy.
Assessment of endothelial function
Endothelial dysfunction is the earliest physiological vascular abnormality that can be measured; it has been shown to correlate well with future CVD in adults. 42 Measurement of endothelium-dependent (flow-mediated) and endotheliumindependent (nitroglycerin-mediated) vasodilatation of the brachial artery (i.e. flow-mediated and nitroglycerin-mediated brachial artery reactivity) is performed by high-resolution ultrasound imaging.
The test is performed under standardised conditions, subjects having been lying supine for at least 10 minutes at a room temperature of 22˚C. Measurements of the brachial artery diameter, and its blood flow, are performed before and immediately after a pneumatic cuff is inflated for approximately 3 to 5 minutes to pressures above the subject's systolic blood pressure. Deflation of the cuff results in reactive hyperaemia and increased blood flow through the brachial artery as part of the process called endotheliumdependent flow-mediated vasodilatation. After a 10-minute rest period, measurement of the baseline brachial artery diameter is repeated. It is repeated again three minutes after a single sublingual dose of nitroglycerin spray, which produces endothelium-independent dilatation. 43 Flow-mediated dilatation of the brachial artery has been shown to be impaired in children with T1DM but no published data exist to date for those children with T2DM. 44, 45 Assessment of arterial stiffness The earliest mechanical abnormality that can be measured in the vasculature is arterial stiffness. Arterial distensibility is a measure of vascular elastic behaviour. 46 It can be measured by assessing changes to vessel diameter during the cardiac cycle (e.g. arterial diastolic wall stress [DWS]) or by pulsewave velocity (PWV) and can be carried out on the carotid or the brachial artery by using high-resolution ultrasonography with colour flow Doppler.
Although arterial distensibility has been found to correlate well with LDL-C levels and BMI, and has been found to be abnormal in children with T1DM, the body of literature on arterial stiffness as a risk factor for CVD events is not as extensive as that on intima-media thickness (IMT) or measurement of flow-mediated dilatation in general. [47] [48] [49] [50] Measurement of arterial intima-media thickness Thickening of the arterial intima and media is considered the earliest measurable anatomical change of atherosclerosis. It precedes clinical atherosclerosis by decades but it has been shown to be a good predictor of CVD events in adults. 51 Over time, dysfunction of the endothelium leads to measurable thickening of the intima and media of the vessel wall of large-and medium-sized muscular arteries and large elastic arteries such as the aorta, carotid and the iliac arteries.
Measurement of IMT by ultrasonography has been shown to improve risk assessment in intermediate-risk patients, especially those older than 50 years of age. It is most commonly done on the carotid artery. Carotid intimamedia thickness (CIMT) measurement is performed on the distal 1 cm segment of the extracranial common carotid arteries, the carotid bifurcations and the proximal 1 cm segment of the internal carotid arteries. 52, 53 IMT has been shown to correlate well with LDL-C, HDL-C and triglyceride levels. It has also been shown to correlate with the presence of hypertension and obesity in other studies. In T1DM, the majority of the studies have also demonstrated increased IMT and a correlation with duration of disease, but this correlation has not been consistent. 44, 45, 50, 54, 55 There are no data on CIMT in children with T2DM.
The prediction of cardiovascular risk While we are developing methods of assessment for CVD in children, our ability to predict future ischaemic CVD events is limited. In general, the methods used for CVD risk assessment and its quantification during the pre-clinical and clinical stages of CVD in adults are fairly well established and, for the most part, standard clinical practice. The same is not true for children. The extremely low incidence of ischaemic CVD in paediatrics makes the predictive value of these parameters difficult to establish. Even though the data reviewed above suggest a strong epidemiological and pathophysiological association in children and youth, clear scientific evidence of a cause and effect relationship between CVD risk factors and subsequent CVD morbidity and mortality in adulthood is still lacking. Considering the overwhelming confirmatory evidence of such a cause and effect relationship originating from adult clinical trials, it would be unethical to subject children to the same kind of trials. Ideally, we would perform randomised clinical trials to prove a cause and effect relationship between known paediatric CVD risk factors, specific interventions, and subsequent CVD event reduction and prevention in adulthood. Inevitably, however, this would require withholding interventions that are highly likely to be beneficial.
Nevertheless, there is still a need for prospective clinical studies in children to serve as a proof of concept for each proposed intervention, to assess the risk-benefit ratio and to demonstrate safety. For these reasons, we must be able to interpret, translate and discover ways to validate in children the scientific evidence from the adult literature. The development and conduct of ethically appropriate clinical trials for children will undoubtedly require use of active comparators, surrogate markers and non-invasive methods for the assessment of early CVD disease and its progression.
Predictive equations
Several equations have been developed to help clinicians to estimate the risk of future CVD in their patients more accurately. These equations are derived from large-scale, prospective cohort studies or randomised clinical trials and help estimate a patient's risk of having a CVD event over the next 5-10 years.
The most widely studied and recommended equations, especially for use in the US, are those derived from the Framingham Heart Study. Since these help to calculate the risk of future CVD events in subjects with no prior history of CVD, they would be the most appropriate equations to use when determining primary prevention strategies. These calculators include the Framingham Risk Calculator (available at http://hin.nhlbi.nih.gov/atpiii/calculator.asp?usertype), the National Cholesterol Education Program (NCEP) Calculator and the American Heart Association (AHA) Calculator, among others. 56 The validity of the Framingham-based equations in the setting of DM has been questioned, since relatively few patients with DM were included in the Framingham cohort, and because these equations exclude serum triglyceride concentrations, which are considered to be an important risk factor in subjects with DM. Therefore, for subjects with DM, other equations have been developed such as the United Kingdom Prospective Diabetes Study (UKPDS) Risk Engine (available for download at http://www.dtu.ox.ac.uk/ riskengine), the Prospective Cardiovascular Munster Study (PROCAM) equation and the American Diabetes Association (ADA) Diabetes PHD (Personal Health Decisions; available at http://diabetes.org/diabetesPHD), which is powered by the Archimedes mathematical model and has been extensively validated against clinical trials. 57, 58 However, in general, the performance of these equations is quite similar to that of the Framingham-based equations.
Unfortunately, none of these equations have been validated for use in children. It is logical to assume that although the risk for CVD events over a period of 10 years will be much lower in children than in adults, the overall lifetime risk for an event may be higher, depending upon the age of onset of T2DM. As discussed in the introduction, we are developing a clearer idea of the relevant inputs into such equations, but we have scant data regarding ultimate overall risk, and may never obtain this due to ethical concerns. Ideally, paediatric formulae would assess lifetime risk, rather than the risk over relatively short timeframes.
Cardiovascular disease in paediatric T2DM: therapeutic interventions
When caring for paediatric patients with T2DM, clinicians face a dilemma. Although many therapies are tied to clear improvement in adult outcomes, very few therapies are studied or even approved in the paediatric population. Unlike many paediatric patients with T1DM, where glucose control is often the primary focus of care in the first few years (microvascular and macrovascular complications are rare at this point), paediatric patients with T2DM, like their adult counterparts, will often present with a combination of obesity, hyperlipidaemia, hypertension and hyperglycaemia. Adult guidelines emphasise addressing all of these factors concurrently, recognising they are all contributory to cardiovascular risk. The last consensus statement from the American Diabetes Association (ADA) regarding management of T2DM in children makes the same point. 59 That statement also provides a helpful algorithm for differentiating T1DM from T2DM in children, which can be difficult.
Obesity should be addressed immediately because loss of weight can improve glycaemic control and even cause a 'remission' of T2DM in patients. Those families who do achieve this should be reminded that the child has proven diabetic potential, and there is every reason to believe that regain of weight will lead to a reappearance of the disease. Optimal methods of weight loss remain controversial.
Lipid management
The management of hyperlipidaemia in paediatric T2DM is challenging as well. Here, the clinician is faced with a wide variety of therapeutic options, with limited data regarding safety and efficacy in children. Recent guidelines from the American Heart Association/American Academy of Pediatrics (AHA/AAP) and recent reviews have helped to clarify treatment goals. 60 The AHA/AAP guidelines reflect a general acceptance of using HMG-coenzyme A reductase inhibitors (statins) in paediatric patients. These drugs were REVIEW initially avoided due to safety concerns, but their efficacy and clear association with improved outcomes has led to their greater emphasis in paediatrics. Most paediatric patients with T2DM will demonstrate the typical lipid pattern associated with insulin resistance (high LDL-C, low HDL-C and high triglycerides).
Interestingly, the AHA/AAP guidelines place T2DM in 'Tier II: moderate risk' while listing T1DM as high risk, which may be counter to the impression of many clinicians. This is a reflection of the limited evidence base in paediatric T2DM and the fact that T1DM often presents much earlier than T2DM in paediatrics. The algorithm is constructed, however, such that almost all patients with T2DM will move into the high-risk category based on obesity, lipids, blood pressure, BMI or a history of physical inactivity. However, no disease-specific guidelines are provided for T2DM. Many clinicians would consider following the guidelines as written for T1DM, which call for strict management of lipids and blood pressure, and pharmaceutical intervention if problems persist beyond a six-month trial of lifestyle intervention. The LDL goal in high-risk paediatric patients is under 100 mg/dL (5.55 mmol/L). Specific goals for other lipid parameters are not provided.
There are now four statins approved by the Food and Drugs Administration (FDA) for use in children aged 10 and older, and the AHA/AAP guidelines reflect that position, recommending therapy only for those in this age range. Doses of pravastatin up to 20 mg are approved in children as young as eight years. 61 The larger studies of these drugs in children were performed in those with familial hypercholesterolaemia, not in T2DM. In the familial hypercholesterolaemia population, some degree of improvement of both CIMT and endothelial function has been shown. 62, 63 There is not, to date, an article assessing either outcome in paediatric T2DM. A real dilemma in the management of female adolescents with T2DM is the use of statins (as well as angiotensin-converting enzyme [ACE] inhibitors, discussed below) in pregnancy. The last set of ADA recommendations emphasises that highly effective contraception and counselling are mandatory in this population.
Hypertension
Hypertension is clearly associated with both macro-and microvascular disease in adult patients with T2DM. The AHA/AAP guidelines for T1DM suggest treatment after six months with lifestyle intervention with a goal of blood pressure < 90th percentile or under 130/80 mmHg, whichever is lower. ACE inhibitor or angiotensin receptor blocker (ARB) therapy would be considered first line in any patient with microalbuminuria, according to ADA guidelines. 64 There is concern about teratogenicity with these drugs, and the importance of contraception should be emphasised in females of child-bearing age. 65 There has been concern about increases in insulin resistance with diuretics and beta blockers, but in established T2DM, overall blood pressure control should not be sacrificed due to these concerns if multiple agents are needed. Few clinicians now feel that beta blockers are contra-indicated in diabetes, despite past concerns about blunting of the hypoglycaemic response.
Platelet inhibition
Due to concerns about Reye's syndrome, the use of aspirin is not recommended in paediatric patients (those under age 19) , and therefore cannot safely be studied in this population. Aspirin therapy is recommended for any adult with diabetes and a history of CVD, for secondary prevention. Aspirin is recommended for primary prevention of CVD in anyone who is over 40 years old or over 30 with risk factors. There are insufficient data to recommend aspirin therapy in the 21-30-year-old age group with no history of CVD. 64 
Hyperglycaemia
The treatment of hyperglycaemia, and thus improvements in HbA 1C , has long been associated with benefits in terms of microvascular outcomes. However, the effects on CVD risk remain less certain. Of great interest currently (but beyond the scope of this paper) is the possibility that certain glucoselowering agents may have additional extra-glycaemic metabolic effects in the setting of diabetes that may be beneficial (weight loss, beta cell preservation, vascular biology, etc). Most paediatric guidelines suggest immediate initiation of insulin for those with severe hyperglycaemia, symptoms related to hyperglycaemia or with any degree of ketosis. Most would then recommend the initiation of metformin once the patient is stabilised. Metformin is now recommended as universal first-line therapy for adults with T2DM, in addition to lifestyle modification. It is approved in paediatric patients aged 10 years and older. 66 The UKPDS suggested that metformin conferred a cardiovascular benefit over both insulin and sulfonylureas, and it may have modest beneficial effects in terms of weight, endothelial function and lipid parameters. 67 The association of metformin with lactic acidosis is questioned by some, and a recent Cochrane analysis failed to demonstrate this association. 68 Importantly, as ketosis is common in newly diagnosed T2DM, most would withhold the drug until the patient was stable.
Insulin is the only other approved drug in paediatric T2DM. It is very efficacious, and most feel it is mandatory if the patient is symptomatic or has significant elevations in the HbA 1C . It is generally not felt to have beneficial cardiovascular effects independent of glycaemic control; however, it may alleviate what is essentially the chronic inflammatory state seen in uncontrolled T2DM. An emerging body of literature suggests that liberal use of insulin and tight glycaemic control improves outcomes in the surgical intensive care unit (ICU) and after coronary artery bypass graft in adults; 69, 70 however, similar benefit could not be confirmed in the medical ICU setting. 71 The mechanism for these associations and the apparent disparities in the study results remain unclear and are under investigation.
None of the drugs discussed beyond this point are formally approved for paediatric use.
Sulfonylureas are clearly effective at lowering blood glucose and HbA 1C , and some paediatric guidelines recommend their use. 72 There is little to suggest direct CVD benefits associated with sulfonylureas aside from their ability to lower HbA 1C ; indeed, some feel there are potential negative cardiovascular effects from some of these drugs. 73 A recent study showed that therapy with a sulfonylurea provides the least durable response when compared with thiazolidinediones and metformin, suggesting they do not improve beta cell function over the long term. 74 There is associated weight gain and a risk of hypoglycaemia with sulfonylurea therapy. They are highly cost-effective and can work well in conjunction with insulin sensitisers.
Glitinides (non-sulfonylurea secretagogues) offer a theoretical advantage in that they are shorter-acting and provide more precise insulin release, with a side-effect profile similar to that of sulfonylureas. They are typically given before meals, as are alpha-glucosidase inhibitors, which inhibit carbohydrate digestion. The latter class are not associated with weight gain or hypoglycaemia but can be associated with significant gastrointestinal side effects, particularly flatulence. Adherence is a potential problem with both of these drugs, due to the requirements for frequent dosing.
Thiazolidinediones (TZDs) are perhaps the most intriguing, but clearly the most controversial, compounds when considering vascular disease in paediatric T2DM. When used as monotherapy, the response seems to be more durable than that to either sulfonylurea or metformin. They have been shown to improve a variety of intermediate measures of CVD in adults, but their ability to prevent CVD events is the topic of vigorous debate. 75, 76 At the time of writing, one meta-analysis suggests the potential for an increased risk of atherosclerotic CVD events associated with rosiglitazone. A similar meta-analysis, as well as a randomised controlled prospective trial performed with pioglitazone, showed no evidence for an increase in ischaemic cardiovascular events and suggested potential risk reduction. [76] [77] [78] [79] Both drugs clearly lead to fluid retention, which can precipitate or worsen signs and symptoms of congestive heart failure in adults, but this is rarely a concern in paediatrics. They generally do not cause hypoglycaemia, but are associated with weight gain. The Treatment Options for T2DM in Adolescents and Youth (TODAY) trial is presently underway, comparing rosiglitazone, metformin, and metformin plus lifestyle intervention in a group of 10-17-year-olds. The primary outcome in each arm is time to loss of glycaemic control, but secondary outcomes, including CVD risk factor monitoring, are being assessed. 80 An emerging concern for the paediatric population when considering long-term therapy with these agents is that adult data suggest a possible detrimental effect on bone mineral density and an increase in fracture risk. 81 Incretin modulators are another attractive group of compounds. The available injectable form (exenatide) is associated with weight loss, and is generally not associated with hypoglycaemia except when used with agents known to cause hypoglycaemia. Sitagliptin, a DPP-IV inhibitor, is an oral agent that is not associated with weight loss, does not cause hypoglycaemia, and leads to improvements in HbA 1C that are similar to those seen with metformin treatment. The amylin analogue pramlintide, also injectable, seems to have similar benefits to exenatide and is (unlike exenatide) approved for use with insulin. Long-term cardiovascular outcomes studies in paediatric or adult patients using these agents are not yet available.
A dilemma for the paediatrician and the patient can be the complexity of a regimen for T2DM treatment, which can often involve expensive polypharmacy. For that reason, some may advocate the use of metformin and insulin alone for glycaemic control, both of which are approved in paediatrics and have established safety records. As noted above, other agents in various combinations may have advantages in terms of insulin sensitisation, weight loss, beta cell preservation and vascular function.
Conclusion
The paediatrician or paediatric endocrinologist faces several challenges in treating paediatric T2DM. The lack of approved drugs and limitations in outcomes data can make treatment decisions difficult. The need to study very large populations to detect cardiovascular events, and ethical concerns involved in conducting these types of studies, will limit our ability to obtain these data. However, the data that are available in this regard are alarming. Data on paediatric T2DM in the Pima Indian population suggest that those with onset in youth face a death rate that is triple that of the non-diabetic population when they reach adulthood. 82 In contrast, Pima Indians with adult-onset T2DM have a death rate that is 1.4 times that of the non-diabetic population. The chance of going on to end-stage renal disease is five times higher if the onset of T2DM is in youth rather than adulthood. Therefore, it is possible that extrapolating adult outcomes data to the paediatric population may actually underestimate the cardiovascular risk in this population.
The biochemical and imaging tools that are becoming available to assess various states of vascular dysfunction may be used in a variety of ways. If used as a screening modality, this information may help us decide when and how to intervene in the pre-diabetic or glucose-intolerant state by defining when early vascular disease is occurring. The cost-effectiveness of these tools will need to be established before they are applied to large populations. This avenue of research may ultimately lead to the development of simple and inexpensive ways to risk-stratify the huge number of patients 'at risk' for T2DM. This may have implications for early intervention by general paediatricians and family physicians, as well as for public health policy.
Patients with established T2DM should be assumed to be a very high-risk group and should have immediate, aggressive intervention for weight and lipid management, glycaemic control and hypertension. Aggressive treatment may require multiple, potentially unapproved medications. A priority should be establishing safety and efficacy information for a variety of drugs that may be potentially useful in T2DM in children and youth. Biochemical and imaging tools will probably have to serve as surrogate markers of cardiovascular outcomes in the absence of long-term data in large paediatric populations.
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